← Back to All US Stocks

Omada Health, Inc. (OMDA) Stock Fundamental Analysis & AI Rating 2026

OMDA Nasdaq Services-Health Services DE CIK: 0001611115
Recently Updated • Analysis: Apr 13, 2026 • SEC Data: 2025-12-31
BUY
72% Conf
Pending
Analysis scheduled

📊 OMDA Key Takeaways

Revenue: $260.2M
Net Margin: -4.9%
Free Cash Flow: $16.9M
Current Ratio: 3.60x
Debt/Equity: 0.00x
EPS: $-0.35
AI Rating: BUY with 72% confidence
Omada Health, Inc. (OMDA) receives a BUY rating with 72% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $260.2M, net profit margin of -4.9%, and return on equity (ROE) of -5.6%, Omada Health, Inc. demonstrates strong fundamentals in the Services sector. Below is our complete OMDA stock analysis for 2026.

Is Omada Health, Inc. (OMDA) a Good Investment?

Claude

Omada Health demonstrates strong revenue acceleration (53.2% YoY) with exceptional unit economics (65.7% gross margin) and a fortress balance sheet ($222M cash, zero debt). The company is rapidly approaching profitability with net losses improving 72.9% YoY while maintaining positive free cash flow, indicating quality growth and near-term path to sustained profitability.

Why Buy Omada Health, Inc. Stock? OMDA Key Strengths

Claude
  • + Exceptional revenue growth of 53.2% YoY demonstrates strong market demand
  • + Excellent gross margin of 65.7% shows strong unit economics and pricing power
  • + Fortress balance sheet with $222M cash (73% of total assets), zero debt, and 3.60x current ratio provides significant runway
  • + Positive free cash flow of $16.9M despite net losses indicates high-quality business model
  • + Rapidly improving profitability with net loss reducing 72.9% YoY, showing trajectory toward breakeven

OMDA Stock Risks: Omada Health, Inc. Investment Risks

Claude
  • ! Currently unprofitable with operating loss of $12.0M and net loss of $12.8M - path to sustained profitability not yet proven
  • ! Negative operating margin (-4.6%) and net margin (-4.9%) indicate company is scaling faster than cost structure allows
  • ! Significant insider Form 4 activity (15 filings in 90 days) may signal uncertainty among company insiders
  • ! Health services sector is competitive with pricing pressure and regulatory risk not fully apparent in financials
  • ! Dependency on continued high growth rates to reach profitability - growth deceleration would extend breakeven timeline

Key Metrics to Watch

Claude
  • * Operating margin trajectory and timeline to breakeven
  • * Revenue growth sustainability as customer base scales
  • * Operating cash flow conversion rate and cash burn runway
  • * Customer acquisition costs and lifetime value economics in SEC filings

Omada Health, Inc. (OMDA) Financial Metrics & Key Ratios

Revenue
$260.2M
Net Income
$-12.8M
EPS (Diluted)
$-0.35
Free Cash Flow
$16.9M
Total Assets
$305.4M
Cash Position
$222.0M

💡 AI Analyst Insight

Strong liquidity with a 3.60x current ratio provides a solid financial cushion.

OMDA Profit Margin, ROE & Profitability Analysis

Gross Margin 65.7%
Operating Margin -4.6%
Net Margin -4.9%
ROE -5.6%
ROA -4.2%
FCF Margin 6.5%

OMDA vs Services Sector: How Omada Health, Inc. Compares

How Omada Health, Inc. compares to Services sector averages

Net Margin
OMDA -4.9%
vs
Sector Avg 10.0%
OMDA Sector
ROE
OMDA -5.6%
vs
Sector Avg 16.0%
OMDA Sector
Current Ratio
OMDA 3.6x
vs
Sector Avg 1.5x
OMDA Sector
Debt/Equity
OMDA 0.0x
vs
Sector Avg 0.7x
OMDA Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Omada Health, Inc. Stock Overvalued? OMDA Valuation Analysis 2026

Based on fundamental analysis, Omada Health, Inc. has mixed fundamental signals relative to the Services sector in 2026.

Return on Equity
-5.6%
Sector avg: 16%
Net Profit Margin
-4.9%
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Omada Health, Inc. Balance Sheet: OMDA Debt, Cash & Liquidity

Current Ratio
3.60x
Quick Ratio
3.54x
Debt/Equity
0.00x
Debt/Assets
24.8%
Interest Coverage
N/A
Long-term Debt
$0.0

OMDA Revenue & Earnings Growth: 5-Year Financial Trend

OMDA 5-year financial data: Year 2025: Revenue $260.2M, Net Income -$67.5M, EPS $-9.52.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Omada Health, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-9.52 indicates the company is currently unprofitable.

OMDA Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
6.5%
Free cash flow / Revenue

OMDA Quarterly Earnings & Performance

Quarterly financial performance data for Omada Health, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $45.5M -$3.2M $-0.06
Q2 2025 $41.2M -$5.3M $-0.24

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Omada Health, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$18.3M
Cash generated from operations
Capital Expenditures
$1.3M
Investment in assets
Dividends
None
No dividend program

OMDA SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Omada Health, Inc. (CIK: 0001611115)

📋 Recent SEC Filings

Date Form Document Action
Apr 10, 2026 4 xslF345X06/form4.xml View →
Apr 7, 2026 4 xslF345X06/form4.xml View →
Apr 7, 2026 4 xslF345X06/form4.xml View →
Apr 7, 2026 4 xslF345X06/form4.xml View →
Apr 7, 2026 4 xslF345X06/form4.xml View →

Frequently Asked Questions about OMDA

What is the AI rating for OMDA?

Omada Health, Inc. (OMDA) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.

What are OMDA's key strengths?

Claude: Exceptional revenue growth of 53.2% YoY demonstrates strong market demand. Excellent gross margin of 65.7% shows strong unit economics and pricing power.

What are the risks of investing in OMDA?

Claude: Currently unprofitable with operating loss of $12.0M and net loss of $12.8M - path to sustained profitability not yet proven. Negative operating margin (-4.6%) and net margin (-4.9%) indicate company is scaling faster than cost structure allows.

What is OMDA's revenue and growth?

Omada Health, Inc. reported revenue of $260.2M.

Does OMDA pay dividends?

Omada Health, Inc. does not currently pay dividends.

Where can I find OMDA SEC filings?

Official SEC filings for Omada Health, Inc. (CIK: 0001611115) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is OMDA's EPS?

Omada Health, Inc. has a diluted EPS of $-0.35.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is OMDA a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Omada Health, Inc. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.

Is OMDA stock overvalued or undervalued?

Valuation metrics for OMDA: ROE of -5.6% (sector avg: 16%), net margin of -4.9% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.

Should I buy OMDA stock in 2026?

Our dual AI analysis gives Omada Health, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is OMDA's free cash flow?

Omada Health, Inc.'s operating cash flow is $18.3M, with capital expenditures of $1.3M. FCF margin is 6.5%.

How does OMDA compare to other Services stocks?

Vs Services sector averages: Net margin -4.9% (avg: 10%), ROE -5.6% (avg: 16%), current ratio 3.60 (avg: 1.5).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Browse: Buy Stocks
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 13, 2026 | Data as of: 2025-12-31 | Powered by Claude AI